ID: ALA5178934

Max Phase: Preclinical

Molecular Formula: C44H82N2O9S

Molecular Weight: 815.21

Representations

Canonical SMILES:  CCCCCCCCCCCCCCCC(=O)OCC(CSC[C@H](NC(C)=O)C(=O)N[C@@H](CO)C(=O)OC)OC(=O)CCCCCCCCCCCCCCC

Standard InChI:  InChI=1S/C44H82N2O9S/c1-5-7-9-11-13-15-17-19-21-23-25-27-29-31-41(49)54-34-38(35-56-36-40(45-37(3)48)43(51)46-39(33-47)44(52)53-4)55-42(50)32-30-28-26-24-22-20-18-16-14-12-10-8-6-2/h38-40,47H,5-36H2,1-4H3,(H,45,48)(H,46,51)/t38?,39-,40-/m0/s1

Standard InChI Key:  TWMUCEFSQRKSOZ-MIXXVGDRSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 815.21

Molecular Weight (Monoisotopic): 814.5741

AlogP: 9.29

#Rotatable Bonds: 40

Polar Surface Area: 157.33

Molecular Species: NEUTRAL

HBA: 10

HBD: 3

#RO5 Violations: 2

HBA (Lipinski): 11

HBD (Lipinski): 3

#RO5 Violations (Lipinski): 3

CX Acidic pKa: 11.42

CX Basic pKa:

CX LogP: 10.50

CX LogD: 10.50

Aromatic Rings: 0

Heavy Atoms: 56

QED Weighted: 0.03

Np Likeness Score: 0.34

References

1. Kaur A, Piplani S, Kaushik D, Fung J, Sakala IG, Honda-Okubo Y, Mehta SK, Petrovsky N, Salunke DB..  (2022)  Stereoisomeric Pam₂CS based TLR2 agonists: synthesis, structural modelling and activity as vaccine adjuvants.,  13  (5.0): [PMID:35694694] [10.1039/d1md00372k]

Source

Source(1):

• Scientific Literature